Approvals
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
FDA Approval For Novartis’s Sickle Cell Treatment Adakveo
One of a new wave of treatments, Novartis has focused on proving its drug cuts vaso-occlusive crises (VOCs), or pain crises.
Pipeline Watch: Lumasiran, Empagliflozin Major Clinical Trial Starts
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Merck’s Ervebo Becomes World’s First Approved Ebola Vaccine
Merck Sharp & Dohme will begin manufacturing licensed doses of Ervebo in Germany and will continue to send investigational vaccine doses to Democratic Republic of Congo.
GW Gets Two Cannabis-Based Meds Backed By NICE
Pipeline Watch: Phase III Readouts For Ibrexafungerp, Reloxaliase
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Pipeline Watch: Phase III Starts With Trofinetide, Gepotidacin
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Astellas Gets Europe Okay For AML Drug Xospata
Pipeline Watch: Phase III Readouts For Somatrogon, Fevipiprant
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Gene And Cell Therapies In Asia: New Korean Law To Change Landscape Of Cutting Edge Biologics
South Korea will undergo many changes as it gears up for a new law on cutting edge regenerative medicine and biologics, which will be implemented next year. Until then, further discussions will be needed to set details of the rules that can step up the industry’s competitiveness and bring the country more in line with global standards.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.